Overview
Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
Status:
Completed
Completed
Trial end date:
2016-10-17
2016-10-17
Target enrollment:
0
0
Participant gender:
All
All
Summary
To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion Criteria:- patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension (PAH)
and is currectly enrolled in a long-term extension study (CQTI571A2301E1) in Japan.
- Patient is currently benifitting form the treatment with QTI571 in the opinion of the
investigator.
Exclusion Criteria:
- Patient has been permanently discontinued from QTI571 study treatment in the parent
study.
- Concomitant use of oral vitamin K antagonist medication.